ClinicalTrials.gg
Not yet recruitingNCT07539181Updated Nov 12, 2026

Disclosing Agents as Photosensitizers in aPDT for Biofilm Control in Children

An interventional study of Mechanical Prophylaxis and aPDT with Erythrosine in Dental Plaque, sponsored by University of Nove de Julho. Not yet recruiting. Open to participants aged 3 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Nove de Julho · Not applicable, Interventional, and Treatment

How we know

Updated Nov 12, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
3 Years to 7 Years
Sex
All
01

Study summary

This randomized controlled clinical trial aims to evaluate the immediate antimicrobial effectiveness and clinical feasibility of blue LED-mediated antimicrobial photodynamic therapy (aPDT) using plaque-disclosing agents as photosensitizers in children aged 3 to 7 years classified as having high caries risk. Seventy-five participants will be randomly allocated to three parallel groups: mechanical prophylaxis, aPDT with erythrosine, or aPDT with GC TriPlaque ID Gel. Dental biofilm will be assessed at baseline (T0) and immediately after the intervention (T1) during the same clinical session. The primary outcome will be the change in viable microbial load expressed as log10 CFU/mL. Secondary and exploratory microbiological assessments will include quantitative polymerase chain reaction (qPCR) and 16S rRNA gene sequencing, respectively. Clinical feasibility will be assessed based on intervention time and children's behavioral acceptance.

Read the detailed description

This randomized controlled clinical trial will evaluate the immediate antimicrobial effectiveness and clinical feasibility of blue LED-mediated antimicrobial photodynamic therapy (aPDT) using plaque-disclosing agents as photosensitizers in children aged 3 to 7 years classified as having high caries risk. A total of 75 children will be randomly allocated into three parallel groups (n=25 per group): (1) mechanical prophylaxis (control group), (2) aPDT using erythrosine as a photosensitizer, and (3) aPDT using GC TriPlaque ID Gel as a photosensitizer. Dental biofilm samples will be collected at baseline (T0) and immediately after the intervention (T1), during the same clinical session. At each assessment time point, three separate dental biofilm samples will be collected using sterile No. 0 curettes from the cervical third of the buccal surface of the study tooth, a primary maxillary molar. To ensure comparability between assessments, pre- and post-intervention samples will be collected, in all groups, from the same anatomical site. One sample will be designated for culture-based colony-forming unit (CFU) analysis, one for quantitative polymerase chain reaction (qPCR), and one for 16S rRNA gene sequencing. The primary outcome will be the change in viable microbial load, expressed as log10 CFU/mL, from baseline to immediately after the intervention. qPCR will be used as a secondary microbiological outcome to quantify selected microorganisms associated with caries, whereas 16S rRNA gene sequencing will be used as an exploratory outcome to assess microbial community composition and diversity. Clinical feasibility will be assessed based on intervention time and children's behavioral acceptance. No longitudinal follow-up is planned.

02

Conditions studied

  • Dental Plaque

Browse trials for

03

In context

Dental Plaque

354 studies on the registry are indexed under Dental Plaque; 61 are open to participants now.

This study's planned enrollment of 75 is above the median of 56 across 318 interventional studies indexed under Dental Plaque.

Browse Dental Plaque studies →

Lead sponsor

University of Nove de Julho is the lead sponsor of 246 studies on the registry; 52 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 1 (13%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 3 to 7 years
  • Both sexes
  • Good general health status
  • Classified as high caries risk according to the CAMBRA protocol (score ≥ +4 or presence of at least one disease indicator associated with two or more biological risk factors)
  • Written obtained from a parent or legal guardian

Exclusion criteria

Exclusion Criteria:

  • Presence of systemic diseases
  • Use of antibiotics within the last 30 days
  • Use of antimicrobial mouthwash within 48 hours prior to sample collection
  • Presence of structural dental alterations that may interfere with the standardization of the procedure
  • Uncooperative behavior preventing safe clinical examination and intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    Mechanical Prophylaxis (Control)

    Participants will receive mechanical prophylaxis using a Robinson brush at low speed with water, without the use of photosensitizers or blue LED irradiation.

    Procedure: Mechanical Prophylaxis

  • Experimental
    aPDT with Erythrosine

    Participants will receive antimicrobial photodynamic therapy (aPDT) using erythrosine as a photosensitizer followed by blue LED irradiation. Mechanical prophylaxis will be performed after post-intervention sample collection.

    Procedure: aPDT with Erythrosine

  • Experimental
    aPDT with GC TriPlaque ID Gel

    Participants will receive antimicrobial photodynamic therapy (aPDT) using GC TriPlaque ID Gel as a photosensitizer followed by blue LED irradiation. Mechanical prophylaxis will be performed after post-intervention sample collection.

    Procedure: aPDT with GC TriPlaque ID Gel

Interventions

  • ProcedureMechanical Prophylaxis

    Mechanical removal of dental plaque using a Robinson brush at low speed with water, without the use of photosensitizers or light activation.

    Also known as: Dental cleaning

  • ProcedureaPDT with Erythrosine

    Application of erythrosine as a photosensitizer followed by blue LED irradiation using a dental curing light to promote antimicrobial photodynamic therapy.

    Also known as: Antimicrobial photodynamic therapy with erythrosine

  • ProcedureaPDT with GC TriPlaque ID Gel

    Application of GC TriPlaque ID Gel as a photosensitizer followed by blue LED irradiation using a dental curing light to promote antimicrobial photodynamic therapy.

    Also known as: Antimicrobial photodynamic therapy with GC TriPlaque ID Gel

06

What researchers measure

Primary outcomes

  1. Change in viable microbial load of dental biofilm (log10 CFU/mL)

    Dental biofilm samples will be collected from the cervical third of the buccal surface of a primary maxillary molar at baseline (T0) and immediately after the intervention (T1), during the same clinical session. The primary outcome will be the change in viable microbial load, expressed as log10 CFU/mL, determined by culture-based colony-forming unit analysis.

    Time frame: Baseline and Periprocedural

Secondary outcomes

  1. Clinical feasibility of the protocol

    Assessment of the total duration of the clinical procedure, measured in minutes using a stopwatch from the beginning to the end of the intervention, to evaluate the feasibility of the protocol in pediatric patients.

    Time frame: Baseline and Periprocedural

  2. Child behavioral acceptance

    Behavioral response of children during the clinical procedure assessed using the Frankl Behavior Rating Scale (scores 1 to 4), evaluating cooperation and acceptance of the treatment.

    Time frame: Baseline and Periprocedural

  3. Change in selected caries-associated microorganisms quantified by qPCR

    Dental biofilm samples collected at baseline (T0) and immediately after the intervention (T1) will be analyzed by quantitative polymerase chain reaction (qPCR) for selected microorganisms associated with caries. Quantified microbial values derived from standard curves will be used to compare changes between pre- and post-intervention assessments and among study groups.

    Time frame: Baseline and Periprocedural

Other outcomes

  1. Change in dental biofilm microbial community composition and diversity assessed by 16S rRNA gene sequencing

    Dental biofilm samples collected at baseline (T0) and immediately after the intervention (T1) will undergo 16S rRNA gene sequencing. Microbial community composition will be characterized by taxonomic profiling, relative abundance of identified bacterial taxa, alpha diversity, and beta diversity. Changes between pre- and post-intervention assessments and differences among study groups will be explored.

    Time frame: Baseline and Periprocedural

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.

Of 135 non-industry interventional studies with no phase under Dental Plaque, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's planned 5 months is below that.

Counting every sponsor, half of 180 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start May 2026 → Dec 2026, primary completion Jun 2026 → May 2027 and completion Aug 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 20, 2026
StartEst.
Dec 1, 2026was May 2026
Primary completionEst.
May 30, 2027was Jun 2026
CompletionEst.
May 30, 2027was Aug 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 31, 2026→Dec 1, 2026
Nov 12, 2026
Primary completion
Jun 30, 2026→May 30, 2027
Nov 12, 2026
Study completion
Aug 30, 2026→May 30, 2027
Nov 12, 2026
Enrollment
72→75
Nov 12, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedReductionChange in viable microbial load of dental biofilm (log10 CFU/mL)Time frame: Baseline and immediately after the intervention → Baseline and Periprocedural
Nov 12, 2026
Secondary outcomes
2 added
What changed in the outcomes
  • AddedChange in selected caries-associated microorganisms quantified by qPCRTime frame: Baseline and Periprocedural
  • Addedother outcomeChange in dental biofilm microbial community composition and diversity assessed by 16S rRNA gene sequencingTime frame: Baseline and Periprocedural
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date May 31, 2026→Dec 1, 2026
    Primary completion Jun 30, 2026→May 30, 2027
    Study completion Aug 30, 2026→May 30, 2027
    Enrollment 72→75
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedReductionChange in viable microbial load of dental biofilm (log10 CFU/mL)Time frame: Baseline and immediately after the intervention → Baseline and Periprocedural
    Secondary outcomes 2 added
    What changed in the outcomes
    • AddedChange in selected caries-associated microorganisms quantified by qPCRTime frame: Baseline and Periprocedural
    • Addedother outcomeChange in dental biofilm microbial community composition and diversity assessed by 16S rRNA gene sequencingTime frame: Baseline and Periprocedural
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07539181
Responsible party
Sandra Kalil Bussadori (Principal Investigator, University of Nove de Julho) — Principal investigator
First posted
Apr 20, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
May 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Nov 12, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion